Laurus Labs Limited has announced its financial results for the second quarter of the fiscal year 2025-26, along with an interim dividend declaration. The company's Board of Directors convened on October 23, 2025, to approve these significant corporate actions.

Financial Results Approval

The Board of Directors of Laurus Labs has approved the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025. These results have been submitted to the stock exchanges along with limited review reports from the company's statutory auditors, Deloitte Haskins & Sells LLP.

Interim Dividend Declaration

In a move that will likely be welcomed by shareholders, the Board has approved an interim dividend of Rs 0.80 per equity share, which represents 40% of the face value of Rs 2.00 per share for the financial year 2025-26.

Key Dates for Shareholders

For shareholders and potential investors, the following dates are crucial:

The record date is set to determine the eligibility of shareholders for the interim dividend. Investors who are registered as shareholders of Laurus Labs on October 31, 2025, will be eligible to receive the dividend payment.

Board Meeting Details

The Board meeting where these decisions were made commenced at 2:00 PM and concluded at 2:55 PM on October 23, 2025. The company has duly informed the stock exchanges about the outcome of this meeting, in compliance with regulatory requirements.

Investor Access to Financial Results

Laurus Labs has ensured transparency by making the financial results accessible to the public. Investors and interested parties can view the detailed financial results on the company's official website ( www.lauruslabs.com ) as well as on the websites of the BSE ( www.bseindia.com ) and NSE ( www.nseindia.com ).

While the specific financial figures from the Q2 results have not been disclosed in the available information, the approval of results and declaration of an interim dividend suggest that the company's financial position remains stable. Shareholders and market analysts will likely be keen to examine the detailed financial statements to assess Laurus Labs' performance in the current economic environment.

Investors are advised to review the full financial reports and consult with financial advisors before making investment decisions based on this corporate action.

Laurus Labs , a prominent player in the Indian pharmaceutical sector, has announced robust financial results for the second quarter of the fiscal year 2025-26, showcasing significant growth across key metrics.

Financial Highlights

The company's performance for Q2 FY26 demonstrates substantial year-over-year improvements:

Laurus Labs has shown remarkable growth, with its revenue rising to ₹16.50 billion, marking a 35% increase from ₹12.24 billion in the same quarter of the previous year. The company's bottom line saw an even more impressive surge, with consolidated net profit soaring to ₹1.95 billion, compared to ₹198.00 million in Q2 FY25.

Operational Excellence

The company's operational efficiency is evident in its EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) performance. EBITDA doubled from ₹1.79 billion to ₹4.00 billion year-over-year. This substantial increase in EBITDA was accompanied by a significant expansion in the EBITDA margin, which grew from 14.57% to 24.39%, reflecting improved operational efficiency and cost management.

Dividend Announcement

In light of the strong financial performance, the Board of Directors has approved an interim dividend of ₹0.80 per equity share (40%) for the financial year 2025-26. The record date for determining shareholder eligibility has been set as October 31, 2025, with the dividend expected to be paid on or after November 12, 2025.

Looking Ahead

While Laurus Labs has not provided specific forward-looking statements, the substantial growth in revenue and profitability suggests a positive trajectory for the company. The significant margin expansion indicates that Laurus Labs may be benefiting from economies of scale, improved product mix, or successful cost optimization strategies.

Investors and market observers will likely keep a close watch on the company's performance in the coming quarters to see if this growth momentum can be sustained amidst the dynamic pharmaceutical market landscape.